Arrowhead Pharma Stock Price, News & Analysis

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the approval of inducement grants for 38 new employees by its Board of Directors on July 22, 2025. The grants, made under NASDAQ Listing Rule 5635(c)(4), consist of 52,680 restricted stock units in total. These equity awards, which are outside the company's stockholder-approved equity incentive plans, will vest over a four-year period on an annual basis.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) issued a statement regarding its Exclusive License and Collaboration Agreement with Sarepta Therapeutics. The agreement, closed in February 2025, included a $500 million upfront payment and $325 million through stock purchase at $27.25 per share.

The deal includes $250 million in annual installments over 5 years, $300 million in near-term payments for ARO-DM1 trial enrollment, and up to $10 billion in potential milestones plus tiered royalties. Despite Sarepta's recent unrelated setbacks and restructuring, they have prioritized Arrowhead's programs. The agreement includes comprehensive termination provisions that would return assets and IP to Arrowhead if Sarepta fails to meet its financial obligations.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced it will host a webcast and conference call to discuss its fiscal 2025 third quarter financial results on August 7, 2025, at 4:30 p.m. ET. The quarter ended June 30, 2025.

The event will be accessible via live audio webcast through the Events and Presentations page in the Investors section of Arrowhead's website. A replay will be available approximately two hours after the call concludes. Analysts wishing to participate must pre-register through the provided registration link to receive dial-in details.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated the Phase 3 YOSEMITE clinical trial for zodasiran, its RNAi therapeutic targeting ANGPTL3 for treating homozygous familial hypercholesterolemia (HoFH). This rare genetic condition causes severely elevated LDL-cholesterol levels and early cardiovascular disease.

Zodasiran becomes Arrowhead's fourth RNAi candidate to reach late-stage pivotal studies, following plozasiran, fazirsiran (licensed to Takeda), and olpasiran (licensed to Amgen). Phase 2 results showed promising reductions in LDL-C, ApoB, non-HDL-C, and triglycerides in HoFH patients.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has completed enrollment in three Phase 3 clinical studies (SHASTA-3, SHASTA-4, and MUIR-3) for plozasiran, targeting severe hypertriglyceridemia treatment. The studies, involving approximately 2,200 patients across 24 countries, are expected to complete by mid-2026 with topline data release shortly after. The company has already submitted an NDA for plozasiran based on positive Phase 3 PALISADE study results for familial chylomicronemia syndrome, with FDA's PDUFA date set for November 18, 2025. These trials represent significant progress in plozasiran's development pathway, focusing on triglyceride reduction at 12 months as the primary endpoint.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated a Phase 1/2a clinical trial for ARO-ALK7, its novel RNAi therapeutic targeting obesity treatment. The study marks a significant milestone as ARO-ALK7 becomes the first RNAi therapeutic targeting adipose tissue genes to enter clinical trials. The drug, developed using Arrowhead's proprietary TRiM™ platform, works by silencing the Activin receptor-like kinase 7 (ALK7) in adipose tissue. Preclinical studies showed promising results, demonstrating reduced body weight and fat mass while preserving lean muscle. The trial will initially evaluate single and multiple escalating doses in healthy obese subjects as monotherapy, with plans to progress to combination studies with tirzepatide in obese patients with and without type 2 diabetes.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in two major upcoming investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference on June 4 at 9:20 a.m. EDT, and at the 46th Annual Goldman Sachs Global Healthcare Conference on June 9 at 2:00 p.m. EDT. Both presentations will be in a fireside chat format. Interested parties can access the presentation webcasts through the Events and Presentations page in the Investors section of Arrowhead's website.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported strong fiscal Q2 2025 results, marking significant financial and operational progress. The company posted revenue of $542.7 million, compared to no revenue in Q2 2024, and net income of $370.4 million versus a loss of $125.3 million year-over-year. Following a major licensing deal with Sarepta Therapeutics worth $825 million upfront, Arrowhead is now funded into 2028.

The FDA has accepted the NDA for plozasiran for FCS treatment, with a PDUFA date of November 18, 2025. The company's financial position strengthened with total cash resources reaching $1.1 billion as of March 31, 2025. Additionally, CFO Ken Myszkowski will retire, to be succeeded by Daniel Apel effective May 13, 2025.

[ "Revenue surged to $542.7M in Q2 2025 from zero in Q2 2024", "Net income improved to $370.4M from a loss of $125.3M year-over-year", "Secured $825M upfront from Sarepta deal ($500M cash + $325M equity investment)", "FDA accepted NDA for plozasiran with PDUFA date set", "Cash resources increased to $1.1B, with funding secured through 2028", "Potential for $10B in milestone payments from Sarepta partnership" ]

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in two major investor conferences in May 2025. The company will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 11:20 a.m. PDT, and at the 2025 RBC Capital Markets Global Healthcare conference on May 20, 2025, at 2:35 p.m. EDT. Both presentations will be in a fireside chat format and webcasts will be accessible through the Events and Presentations page in the Investors section of Arrowhead's website.